Insud Pharma
Alberto Arruebo Rello, CFA, currently serves as M&A Manager at Insud Pharma since October 2022. Prior to this role, Alberto accumulated extensive experience in M&A at PwC España from July 2017 to October 2022, progressing through positions including Manager, Senior Associate, and Deals Graduate Programme Associate within the M&A Financial Institutions Group, as well as holding associate roles in Real Estate Corporate Finance and Valuations & Strategy. Alberto holds a Master of Business Administration (MBA) from Universidad Pontificia Comillas and an Engineer's degree in Materials Engineering from Universidad Politécnica de Madrid.
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.